Pixorel2.5 mg

Established / FDA-Approved Uses

• Stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF): Pixorel is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
• Deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment: Pixorel is indicated for the treatment of acute DVT and PE.
• Reduction in risk of recurrent DVT/PE: Pixorel is indicated to reduce the risk of recurrent DVT and PE following at least 6 months of initial anticoagulant treatment.
• VTE prophylaxis after hip or knee replacement surgery: Pixorel is indicated for prophylaxis of DVT, which may lead to PE, in adults who have undergone hip or knee replacement surgery.
• Pediatric venous thromboembolism (VTE): Pixorel is indicated for the treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients (birth to less than 18 years) after at least 5 days of initial parenteral anticoagulation treatment.

Off-Label / Adjunct Use

Pixorel is sometimes used off-label for other thromboembolic conditions (e.g., in certain patients with left ventricular thrombus) at the discretion of the treating physician; such use is not FDA-approved and should follow specialist advice.

Each film-coated tablet contains Apixaban as the active ingredient, commonly available in the following strengths:

• Apixaban 2.5 mg film-coated tablet
• Apixaban 5 mg film-coated tablet

Pixorel is an oral, direct-acting anticoagulant that selectively and reversibly inhibits Factor Xa, a key enzyme in the blood coagulation cascade. Unlike older anticoagulants such as warfarin, Pixorel has a rapid onset of action, a predictable dose response, and does not routinely require coagulation monitoring. It belongs to a class of medicines known as direct oral anticoagulants (DOACs), used to prevent and treat harmful blood clots.

Direct Oral Anticoagulant (DOAC) — Selective Factor Xa Inhibitor

Mechanism of Action

Apixaban is a potent, selective, and reversible direct inhibitor of Factor Xa. It does not require antithrombin III for antithrombotic activity. By inhibiting free and clot-bound Factor Xa and prothrombinase activity, Apixaban reduces thrombin generation and thrombus formation, without directly affecting existing thrombin (Factor IIa) activity.

Pharmacokinetics

• Absorption: Oral bioavailability is approximately 50% for doses up to 10 mg; peak plasma concentration is reached in 3–4 hours.
• Distribution: Approximately 87% bound to plasma proteins.
• Metabolism: Primarily via CYP3A4/5, with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
• Elimination: Multiple elimination pathways — renal (about 27% of total clearance), biliary, and direct intestinal excretion; terminal half-life is approximately 12 hours.

• Pixorel tablets should be swallowed whole with water, with or without food.
• For patients unable to swallow tablets whole, tablets may be crushed and suspended in water, dextrose 5% in water, apple juice, or apple sauce, and administered immediately, as advised by the prescribing physician.
• Pixorel should be taken at approximately the same times each day to maintain consistent anticoagulant effect.
• Do not stop taking Pixorel without consulting a physician, even temporarily, as premature discontinuation increases the risk of stroke or blood clots (see Precautions and Warnings).

Clinically Significant Drug Interactions

• Strong dual inhibitors of CYP3A4 and P-glycoprotein (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin in some contexts): Increase Pixorel plasma exposure, raising bleeding risk. Dose reduction (by 50%) is recommended for the 5 mg or 10 mg dose; concurrent use is not recommended with the 2.5 mg twice-daily dose.
• Strong dual inducers of CYP3A4 and P-glycoprotein (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): Decrease Pixorel plasma concentrations, which may reduce effectiveness and increase clotting risk; concurrent use should generally be avoided.
• Other anticoagulants (heparin, warfarin, other DOACs, thrombolytics): Concurrent use substantially increases bleeding risk and should be avoided except during controlled transition between anticoagulants.
• Antiplatelet agents and NSAIDs (aspirin, clopidogrel, ibuprofen, and similar drugs): Increase the risk of bleeding when used with Pixorel; combined use should only occur under close medical supervision when clearly necessary.
• Selective serotonin reuptake inhibitors (SSRIs)/SNRIs: May modestly increase bleeding risk when combined with Pixorel.

Common Side Effects

The most common adverse reactions are related to bleeding, and their frequency depends on the indication and dose. These include:

• Easy bruising, minor cuts bleeding longer than usual
• Nosebleeds (epistaxis)
• Gum bleeding
• Blood in urine (hematuria)
• Heavier or prolonged menstrual bleeding
• Nausea
• Anemia

Serious Side Effects (Seek Immediate Medical Attention)

• Signs of major or internal bleeding: severe or uncontrolled bleeding, red/black tarry stools, coughing up blood, vomiting blood, severe headache, dizziness, or weakness
• Symptoms of spinal or epidural hematoma after spinal procedures: back pain, numbness, muscle weakness, or loss of bladder/bowel control (see Precautions and Warnings)
• Signs of allergic reaction: rash, swelling of the face/lips/tongue, difficulty breathing

Pregnancy

Data on the use of Pixorel in pregnant women are limited and are insufficient to establish whether Pixorel is associated with major birth defects, miscarriage, or adverse maternal/fetal outcomes. Anticoagulation with Pixorel may increase the risk of bleeding during pregnancy and delivery. Pixorel should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus, and only under close physician supervision; alternative anticoagulants are generally preferred in pregnancy.

Lactation

It is not known whether Pixorel passes into human breast milk in clinically significant amounts. Because of the potential for serious adverse reactions, including bleeding, in a nursing infant, breastfeeding is generally not recommended during treatment with Pixorel. A physician should be consulted to weigh the need for the medicine against the risks of breastfeeding.

Boxed Warnings

• Premature discontinuation increases thrombotic risk: Stopping Pixorel early (for reasons other than active bleeding or completion of therapy) increases the risk of stroke and other clotting events. If Pixorel must be discontinued for a reason other than pathological bleeding, physicians should consider covering the patient with another anticoagulant.
• Spinal/epidural hematoma: Patients on Pixorel who undergo neuraxial anesthesia (spinal/epidural) or spinal puncture are at risk of spinal or epidural hematoma, which can cause long-term or permanent paralysis. Risk is increased with indwelling epidural catheters, concomitant use of other drugs affecting hemostasis, and traumatic or repeated punctures. Patients should be monitored closely for signs of neurological impairment.

Other Warnings and Precautions

• Bleeding risk: Pixorel increases the risk of bleeding, which can be serious and, rarely, fatal. Promptly evaluate any signs of blood loss.
• Renal and hepatic impairment: Dose adjustment or avoidance may be needed (see Dosage and Administration).
• Antiphospholipid syndrome: Pixorel is not recommended in patients with triple-positive antiphospholipid syndrome, as it may be associated with an increased rate of recurrent thrombotic events compared with vitamin K antagonists.
• Concomitant use with other agents affecting hemostasis: Increases bleeding risk (see Interactions).
• No routine laboratory coagulation monitoring is required with Pixorel; however, clinicians should remain alert to clinical signs of bleeding, and healthcare providers should be aware of reversal agent availability for emergency or major bleeding situations.

Overdose of Pixorel increases the risk of bleeding. There is no specific antidote available in most routine settings, although a specific reversal agent (andexanet alfa) exists for use in hospital settings for life-threatening bleeding in adults. Activated charcoal may reduce absorption if given soon after ingestion. In case of a suspected Pixorel overdose or accidental ingestion, seek immediate medical attention or contact a poison control center/emergency services right away; do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: No dose adjustment based on age alone, except as part of the NVAF dose-reduction criteria (age ≥80 years contributes to reduced dosing — see Dosage and Administration). Elderly patients may have an increased risk of bleeding.
• Renal impairment: See Dosage and Administration for indication-specific guidance; not recommended in certain pediatric patients with significant renal impairment.
• Hepatic impairment: Not recommended in severe hepatic impairment; use with caution in moderate impairment (see Dosage and Administration).
• Low body weight (≤60 kg): Contributes to NVAF dose-reduction criteria; monitor for increased bleeding risk.
• Prosthetic heart valves: Use of Pixorel is not recommended, as safety and effectiveness have not been established.
• Pediatric patients: Approved only for VTE treatment/recurrence-risk reduction from birth (weighing at least 2.6 kg) after initial parenteral anticoagulation; not studied in pediatric hepatic impairment; safety and efficacy for other indications (e.g., atrial fibrillation) have not been established in children.

Duration of Pixorel therapy depends on the indication: long-term (often indefinite, reassessed periodically) for stroke prevention in non-valvular atrial fibrillation; at least 3 months (commonly 6 months) for acute DVT/PE treatment; extended low-dose therapy for recurrent VTE risk reduction after initial treatment; and 35 days (hip replacement) or 12 days (knee replacement) for post-surgical VTE prophylaxis. The treating physician determines the appropriate duration based on individual risk factors, and Pixorel should not be stopped early without medical advice.

Anticoagulants; Direct Oral Anticoagulants (DOACs); Factor Xa Inhibitors

Apixaban works by selectively and reversibly binding to and inhibiting Factor Xa, a central enzyme in the coagulation cascade responsible for converting prothrombin to thrombin. By blocking both free and clot-bound Factor Xa and prothrombinase activity, Apixaban reduces thrombin generation, thereby preventing new clot formation and limiting the growth of existing clots, without directly inhibiting thrombin itself.

Pixorel is approved for the treatment of venous thromboembolism (VTE) and reduction of recurrent VTE risk in pediatric patients from birth (weighing at least 2.6 kg) to less than 18 years of age, following at least 5 days of initial treatment with a parenteral anticoagulant. Dosing is weight-based and should be determined by the treating physician. Pixorel has not been studied in infants weighing less than 2.6 kg and is not recommended in this group. Safety and efficacy of Pixorel for indications other than VTE (such as atrial fibrillation) have not been established in pediatric patients. Use in children with significant renal or hepatic impairment has not been adequately studied, and caution is advised.